1465 related articles for article (PubMed ID: 26795286)
21. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
[TBL] [Abstract][Full Text] [Related]
23. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
25. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract][Full Text] [Related]
26. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of [
Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
[No Abstract] [Full Text] [Related]
29. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Kesavan M; Turner JH; Meyrick D; Yeo S; Cardaci G; Lenzo NP
Cancer Biother Radiopharm; 2018 Sep; 33(7):274-281. PubMed ID: 29989440
[TBL] [Abstract][Full Text] [Related]
30. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
31. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
32. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
33. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
36.
Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
[TBL] [Abstract][Full Text] [Related]
37. [
Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
[TBL] [Abstract][Full Text] [Related]
38. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
39. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
